



## Corrigendum to "Candidate anti-tuberculosis medicines and regimens under clinical evaluation" [Clin Microbiol Infect 30(9) (2024) 1131–1138]

Michael Hoelscher<sup>1, 2, 3, 4, \*</sup>, David Barros-Aguirre<sup>5</sup>, Masoud Dara<sup>6</sup>,  
Norbert Heinrich<sup>1, 2, 3</sup>, Eugene Sun<sup>7</sup>, Christoph Lange<sup>8, 9, 10, 11</sup>, Simon Tiberi<sup>12, 13</sup>,  
Charles Wells<sup>14</sup>

<sup>1</sup> Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany

<sup>2</sup> German Centre for Infection Research, Partner Site Munich, Munich, Germany

<sup>3</sup> Fraunhofer Institute ITMP, Immunology, Infection and Pandemic Research, Munich, Germany

<sup>4</sup> Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany

<sup>5</sup> GSK, Tres Cantos, Spain

<sup>6</sup> Otsuka Novel Products GmbH, Munich, Germany

<sup>7</sup> TB Alliance, New York, NY, United States

<sup>8</sup> Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany

<sup>9</sup> German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany

<sup>10</sup> Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany

<sup>11</sup> Baylor College of Medicine and Texas Children Hospital, Global TB Program, Houston, TX, United States

<sup>12</sup> GSK, Brentford, United Kingdom

<sup>13</sup> Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

<sup>14</sup> Bill & Melinda Gates Medical Research Institute, Cambridge, MA, United States

### The authors regret that the following text on funding of this work was not included:

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.cmi.2024.06.016>.

\* Corresponding author. Michael Hoelscher, Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, Leopoldstr 5, 80802 Munich, Germany.  
E-mail address: [hoelscher@lrz.uni-muenchen.de](mailto:hoelscher@lrz.uni-muenchen.de) (M. Hoelscher).